International Journal of Drug Delivery Technology
Volume 14, Issue 3

Harnessing the Power of Curcumin: Evaluating Its Efficacy as an Antileishmanial Agent in the Fight Against Leishmaniasis

Minal Gopichand Ambilkar1, Gaurav Sanjay Mude2, Aashumi Ashok Kucheriya3, Rahul Madhukar Bhoyar4

1Department of Clinical Research Allied Health Science, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.

2Department of Pharmacology, Datta Meghe College of Pharmacy, Wardha Maharashtra, India.

3Department of Clinical Research Allied Health Science, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.

4Department of Pathology, Kasturba Gandhi Hospital, Wardha, Maharashtra, India.

Received: 25th March, 2024; Revised: 08th July, 2024; Accepted: 14th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

Over 100 countries are impacted by the dangerous parasite disease leishmaniasis, which is categorized as a neglected tropical disease (NTD). Protozoan parasites use sandflies and other vectors to spread the disease. Herbal compounds like turmeric curcumin have demonstrated promise in the treatment of parasitic illnesses despite their limited bioavailability and water solubility. From small, self-healing skin lesions to serious intestinal infections, leishmaniasis can cause a wide range of illnesses in humans. Since there isn’t a gold standard test for one type, mucocutaneous leishmaniasis (MCL), it can be difficult to diagnose. Treatments for MCL can be quite harmful, which emphasizes how crucial a correct diagnosis. This study aims to assess the diagnostic performance of PCR (polymerase chain reaction) for MCL and to compare the findings with the authors’ most recent clinical research findings.

Keywords: Leishmaniasis, Curcumin, Antileishmanial, Protozoan parasites, Anti-inflammatory parasite.

Key Messages: In low-resource situations, curcumin shows significant promise as an inexpensive, natural medicine to treat leishmaniasis. Although its antileishmanial qualities, affordability, and safety are encouraging, more study is required to improve the dosage, formulation, and clinical efficacy.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.88

How to cite this article: Ambilkar MG, Mude GS, Kucheriya AA, Bhoyar RM. Harnessing the Power of Curcumin: Evaluating Its Efficacy as an Antileishmanial Agent in the Fight Against Leishmaniasis. International Journal of Drug Delivery Technology. 2024;14(3):1890-1895.

REFERENCES

  1. Kunchandy E, Rao MNA. Oxygen radical scavenging activity of curcumin. International Journal of Pharmaceutics 1990; 58(3): 237-240 Available from: https://doi.org/10.1016/0378- 5173(90)90201-E
  2. Elamin M, Al-Olayan E, Abdel-Gaber R, Yehia RS. Anti- proliferative and apoptosis induction activities of curcumin on Leishmania major. Revista Argentina de Microbiología2021 Jul 1;53(3):240–7.Availabe from : https://doi.org/10.1016/j. 2020.08.004
  3. Saberi R, Fakhar M, Asfaram S, A k ht a r i J, Nakhaei M, Keighobadi A Systematic Literature Review of Curcumin with Promising Antileishmanial Activity. Infectious Disorders - Drug Target 21(3):363–9. Available from DOI: 10.2174/1871526520666200525013458
  4. Tiwari B, Pahuja R, Kumar P, Rath SK, Gupta KC, Goyal N. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Antimicrob Agents Chemother. 2017 Feb 23;61(3):10.1128/ aac.01169-16.Available form . https://doi.org/10.3762/bjnano.15.4
  5. Salehi B, Abu-Darwish MS, Tarawneh AH, Cabral C, Gadetskaya AV, Salgueiro L, Hosseinabadi T, Rajabi S, Chanda W, SharifiRad Antimicrobial resistance collaborators global burden of bacterialantimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629-55. doi: 10.1016/S0140-6736(21)02724-0.Availablefrom : doi: 10.3390/ijerph19084666
  6. David CV, Craft Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22(6):491–502.Available from DOI: 10.1016/j.jaad.2014.09.014
  7. Rastogi v, nirwan p. cutaneous leishmaniasis: an emerging infection in a non-endemic area and a brief Indian Journal of Medical Microbiology 2007 jul 1;25(3):272–5.Available from https://doi.org/10.1016/S0255-0857(21)02121-6
  8. Clemente CM, Murillo J, Garro AG, Arbeláez N, Pineda T, Robledo SM, et al. Piperine, quercetin, and curcumin identified as promising natural products for topical treatment of cutaneous leishmaniasis. Parasitol 2024 Apr 18;123(4):185.Available from https://doi.org/10.1016/j.biocel.2008.06.010
  9. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis Expert Review of Anti-infective Therapy 2010 Apr 1;8(4):419–33.Available from https://doi.org/10.1586/eri.10.19
  10. Remadi L, Haouas N, Chaara D, Slama D, Chargui N, Dabghi R, et al. Clinical Presentation of Cutaneous Leishmaniasis caused by Leishmania major. Dermatology. 2017 Mar 3;232(6):752–9. Available from DOI: 10.1159/000456543
  11. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management. Actas Dermo-Sifiliográficas (English Edition) 2015 Dec 1;73(6):911–26. Available from DOI: 10.1016/j.jaad.2014.09.014
  12. Moore EM, Lockwood Treatment of Visceral Leishmaniasis. Journal of Global Infectious Diseases2010;2(2):151–8.Available from DOI: 10.4103/0974-777X.62883
  13. Bailey MS, Lockwood DNJ. Cutaneous leishmaniasis. Journal of Vector Borne Diseases. 2007 Mar 1;25(2):203–11.Available from DOI: 10.1016/j.clindermatol.2006.05.008
  14. De Vries HJC, Schallig HD. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments. Journal of Vector Borne Diseases. 2022 Nov 1;23(6):823–40. Available from DOI: 10.1007/s40257-015-0114-z
  15. Kunchandy E, Rao MNA. Oxygen radical scavenging activity of curcumin.International Journal of Pharmaceutics. 1990;58(3):237-240 Available from :http://dx.doi.org/10.1016/ S0378-8741(03)00043-6
  16. Sundar S, Chakravarty J, Meena LP. Leishmaniasis: treatment, drug resistance and emerging Parasitology International Journal. 2019 Jan 2;7(1):1–10. Available from :https://www. sciencedirect.com/science/article/abs/pii/S138357692400014X
  17. Croft SL, Sundar S, Fairlamb AH. Dr ug Resistance in Leishmaniasis. Dermatology (2017) 232 (6): 752–759. Available from :DOI: 10.1128/CMR.19.1.111-126.2006
  18. Coutinho De Oliveira B, Duthie MS, Alves Pereira Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis. Human Vaccine Immunother. 2020 Apr 2;16(4):919–30.Available from :doi: 10.1080/21645515.2019.1678998
  19. Chattopadhyay A, Jafurulla Md. A novel mechanism for an old drug: Amphotericin B in the treatment of visceral Biochemical Biophysical Research Communication . 2011 Dec 9;416(1):7–12. Available from :https://doi.org/10.1016/j. bbrc.2011.11.023
  20. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L,Caldeira L, et al. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome). Journal of Infection. 1996 Mar 1;32(2):133–7. Available from https://doi.org/10.1016/S0163-4453(96)91343-2
  21. Trinconi CT, Reimão JQ, Yokoyama-Yasunaka JKU, Miguel DC, Uliana SRB. Combination Therapy with Tamoxifen and Amphotericin B in Experimental Cutaneous Leishmaniasis. Antimicrobical Agents . 2014 Apr 10;58(5):2608–Available from :doi: 10.1128/AAC.01315-13
  22. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: A reviewof field efficacy trials. Iranian Biomedical Journal. 2008 Dec 9;26(52):6759–67. Available from doi: 10.52547/ibj.26.1.35
  23. Wylie CE, Carbonell-Antoñanzas M, Aiassa E, Dhollander S, Zagmutt FJ, Brodbelt DC, et al. A systematic review of the efficacy of prophylactic control measures for naturally-occurring canine leishmaniosis, part I: Vaccinations. Emerging Infectious 2019 Dec;. 2014 Nov 1;117(1):7–18. Available from: doi: 10.3201/eid2512.190164
  24. Duthie MS, Raman VS, Piazza FM, Reed The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine. 2012 Jan 5;30(2):134–41. Available from doi: 10.1016/j.vaccine.2011.11.005
  25. Sundar S, Singh B. Identifying vaccine targets for anti- leishmanial vaccine Expert Rev Vaccines. 2014 Apr;13(4):489– 505.Available from :doi: 10.1586/14760584.2014.894467
  26. Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS Neglected Tropical Disease. 2017 May 12;11(5):e0005527. Available from :doi: 10.1371/journal. 0005527
  27. Kunchandy E, Rao MNA. Oxygen radical scavenging activity of curcumin. International Journal of Pharmaceutics, 58, 237-1990;58(3).29. Available from : http://dx.doi.org/10.1016/ S0378-8741(03)00043-6
  28. Shimizu K, Funamoto M, Sunagawa Y, Shimizu S, Katanasaka Y, Miyazaki Y, et Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases. European Cardiology Review. 2019 Jul 11;14(2):117–22. Available from: doi: 10.15420/ecr.2019.17.2
  29. Chattopadhyay I, Biswas K, Bandyopadhyay U, Banerjee RK. Turmeric and curcumin: Biological actions and medicinal Journal of Food Drug Analysis . . 2004;87(1):44–53.Available from: doi: 10.38212/2224-6614.3454
  30. Garnier T, Mäntylä A, Järvinen T, Lawrence J, Brown M, Croft In-vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrobiological Chemother. 2007 Oct 1;60(4):802–10.Available from : doi: 10.1093/jac/dkm303.
  31. Redkar M, Patil S, Nalkar S, Pandav A comprehensive review on floating pulsatile drug delivery system. World Journal of Pharmaceutical Research. 2019; 8(8):304-329. DOI: 10.20959/ wjpr20198-15265
  32. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled t rial on the anti-inf lammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Annals of Clinical Microbiology and Antimicrobials.2012 Nov 1;49(6):580–8.Available from: DOI: 1258/acb.2012.012040
  33. Hewlings SJ, Kalman DS. Curcumin: A Review of Its’ Effects on Human Foods. 2017 Oct 22;6(10):92.Available from: doi: https://doi.org/10.54393/df.v1i02.15
  34. Costa-da-Silva AC, Nascimento D de O, Fer reira J R M, Guimarães-Pinto K, Freire-de-Lima L, Morrot A, et Immune Responses in Leishmaniasis: An Overview.Journal of Nutritional and Food Sciences 2022 Apr;7(4):54. Available from doi: 10.3390/ tropicalmed7040054:
  35. Varalakshmi Ch, Ali AM, Pardhasaradhi BVV, Srivastava RM, Singh S, Khar Immunomodulatory effects of curcumin: In-vivo. Tropical Medicine and Infectious Disease . 2022 Apr;2008 May 1;8(5):688–700. Available from doi: 10.1016/j. intimp.2008.01.008
  36. Jakubczyk K, Drużga A, Katarzyna J, Skonieczna-ŻydeckaAntioxidant Potential of Curcumin—A Meta-Analysis of Randomized Clinical Trials. Antioxidants (Basel). 2020 Nov; 9(11): 1092..Available from : doi: 10.3390/antiox9111092
  37. Papież MA, Krzyściak W, Szade K, Bukowska-Straková K, Kozakowska M, Hajduk K, et al. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive Drug Design Development and Therapy.2016 Feb 4;10:557–70. Available from : doi: 10.2147/ DDDT.S92687
  38. Rashid AE, Ahmed ME, Hamid Evaluation of Antibacterial and Cytotoxicity Properties of Zinc Oxide Nanosponges Synthesized by Precipitation Method against Methicillinresistant Staphylococcus aureus. International Journal of Drug Delivery Technology. 2022, 12(3), 985-989. DOI: 10.25258/ ijddt.12.3.11